ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
100 hedge funds and large institutions have $335M invested in ChemoCentryx, Inc. in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 39 reducing their positions, and 12 closing their positions.
138% more capital invested
Capital invested by funds: $141M → $335M (+$194M)
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
15% more funds holding
Funds holding: 87 → 100 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 39
61% less call options, than puts
Call options by funds: $178K | Put options by funds: $453K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.75M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
+$4.02M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$3.77M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.98M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.56M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$3.17M |
| 4 |
AG
Artal Group
Luxembourg
|
-$2.98M |
| 5 |
BlackRock
New York
|
-$1.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IHM
101
Iguana Healthcare Management
New York
| – | -$595K | -100,000 | Closed |
|
102
Los Angeles Capital Management
Los Angeles,
California
| – | -$540K | -90,684 | Closed |
|
|
SCM
103
Sio Capital Management
New York
| – | -$496K | -83,428 | Closed |
|
|
IG
104
ING Group
Amsterdam,
Netherlands
| – | -$179K | -30,000 | Closed |
|
105
Squarepoint
New York
| – | -$134K | -22,574 | Closed |
|
106
SG Americas Securities
New York
| – | -$78K | -13,113 | Closed |
|
|
ARTA
107
A.R.T. Advisors
New York
| – | -$67K | -11,297 | Closed |
|
108
Parallax Volatility Advisers
San Francisco,
California
| – | -$22K | -3,738 | Closed |
|
109
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -1,500 | Closed |
|
|
DCM
110
Delpha Capital Management
New York
| – | -$2K | -392 | Closed |
|
|
CG
111
Cutler Group
San Francisco,
California
| – | -$2K | -369 | Closed |
|
112
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.59K | -154 | -98% |
|
CCXI Hedge Fund Activity: Q1 2018 in Review
100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q1 2018, worth a combined $335M — up 138% from $141M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CCXI positions and 12 closed out — a net gain of 13 holders — while 26 added to existing stakes and 39 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.8M. The largest seller was BVF Inc, cutting an estimated $3.98M.
- 100 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q1 2018, up from 87 in Q4 2017.
- Funds reported $335M of ChemoCentryx, Inc. stock for Q1 2018, up 138% quarter-over-quarter.
- 25 funds opened new ChemoCentryx, Inc. positions in Q1 2018 and 12 closed out, a net change of +13 holders.
- The largest ChemoCentryx, Inc. buyer in Q1 2018 was Farallon Capital Management, an estimated $9.8M added.
- The largest ChemoCentryx, Inc. seller in Q1 2018 was BVF Inc, an estimated $3.98M sold.
Based on aggregated 13F filings for Q1 2018.